

Date: November 05, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Sub.: Intimation under regulation 30 of Securities and Exchange Board of India (Listing Regulations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, it is hereby informed that, the wholly owned subsidiary of the Company, i.e. Senores Pharmaceuticals, Inc. (“**SPI**”) has entered into a Limited Liability Company Agreement (“**LLCA**”) dated November 04, 2025, whereby SPI has subscribed to 51% of the membership interest in Zoraya Pharmaceuticals, LLC, situated in the state of Delaware, USA, pursuant to which, Zoraya Pharmaceuticals, LLC has become a step-down subsidiary of the Company.

The details as required under Regulation 30 of the Securities and Exchange Board of India (Listing Regulations and Disclosure Requirements) Regulations, 2015 read with the SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed herewith as **Annexure-A**.

This is for your information and records. The same is also being uploaded on the website of the Company at www.senorespharma.com.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Encl.: As mentioned above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Annexure - A
Disclosure under Regulation 30(6) read with Para A (1) of Part A of Schedule III of the Listing Regulations and the SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. No.	Particulars	Description
1.	Name of the Target Company, details in brief such as size, turnover, etc.	Name: Zoraya Pharmaceuticals, LLC Turnover: Not applicable as it is a newly formed entity.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	Not applicable, as this intimation is regarding the formation of a step-down subsidiary of the Company.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Pursuant to the Limited Liability Company Agreement ("LLCA") dated November 04, 2025, the wholly owned subsidiary of the Company i.e., Senores Pharmaceuticals, Inc., has subscribed to 51% membership interest in Zoraya Pharmaceuticals LLC, which, accordingly, has become a step-down subsidiary of the Company.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
6.	Indicative time period for completion of the acquisition	Not applicable
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Not applicable
8.	Cost of acquisition or the price at which the shares are acquired	Not applicable
9.	Percentage of shareholding/ control acquired and/or number of shares acquired	51% of the total membership interest of the step-down subsidiary i.e., Zoraya Pharmaceuticals LLC, has been subscribed by the wholly owned subsidiary of the Company i.e., Senores Pharmaceuticals, Inc. with effect from November 04, 2025.
10.	Brief background about the entity acquired in terms of products/line of	Date of formation of LLC: October 15, 2025

Senores Pharmaceuticals Limited

 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

 P: +91 79 2999 9857 | E: info@senorespharma.com

 W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Sr. No.	Particulars	Description
	business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Date of subscription to membership interest: November 04, 2025 3 Year Turnover: Not applicable Country of presence: United States of America

Committed to
Global Wellness!

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263